Biotech News

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals

MacroGenics (MGNX)MacroGenics2026-05-11 21:20 ESTCompany update

•MacroGenics to receive $122.5 million upfront payment from Bora upon closing •Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora ROCKVILLE, MD, May 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical

Open original release

Related news

MGNXMacroGenics2026-05-14 20:01 EST

MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum

MGNXMacroGenics2026-05-13 20:01 EST

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

ZNTLZentalis2026-06-01 21:00 EST

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZNTLZentalis2026-05-13 20:05 EST

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

KYMRKymera2026-06-08 20:01 EST

Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations

View all latest news

MacroGenics

MacroGenics is an oncology company focused on engineered antibodies and targeted cancer therapies. The company has long been known for antibody engineering and immuno-oncology programs.

Recent company news

MGNXMacroGenics2026-05-14 20:01 EST

MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum

MGNXMacroGenics2026-05-13 20:01 EST

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

MGNXMacroGenics2026-05-11 21:20 EST

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals

MGNXMacroGenics2026-05-04 11:30 EST

MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement

MGNXMacroGenics2026-04-08 20:30 EST

FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study

Stock data

Close: 4.00 USD
Market cap: 257.43M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States